Innovent Biologics Inc

Innovent Biologics announced the expansion of the global Phase 3 MarsLight-11 trial of IBI363, also known as TAK-928, to include patients with non-squamous non-small cell lung cancer. The trial previously evaluated the therapy only in patients with squamous NSCLC whose disease had progressed on or after chemotherapy and immunotherapy. The non-squamous evaluation will run as a new substudy, so MarsLight-11 will now comprise two independent substudies, one in squamous NSCLC and one in non-squamous NSCLC, each testing IBI363 monotherapy against docetaxel in unresectable, locally advanced or metastatic disease that has progressed during or after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. IBI363/TAK-928 is a potential first-in-class alpha-biased IL-2/PD-1 bispecific fusion protein co-developed globally by Innovent and Takeda, and it has received two Fast Track Designations from the U.S. FDA and three Breakthrough Therapy Designations from China NMPA. In October 2025 the two companies signed a license and collaboration agreement covering global co-development and U.S. co-commercialization, with Takeda holding exclusive commercialization rights worldwide outside the U.S. and greater China.

Chinese biopharma shares rallied on Monday after a report that the U.S. Treasury Department is drafting rules that would likely allow American pharmaceutical companies to invest in promising new drugs developed by Chinese firms, excluding those related to pathogens or biotechnology that could be weaponized. Innovent Biologics rose 7% and Akeso gained 8%, while HUTCHMED advanced 3% and Sino Biopharmaceutical added 8%, and the Hang Seng Biotech Index climbed more than 5%. The report follows Friday's news of the pending Treasury rules and comes as Chinese President Xi Jinping is set to meet with his American counterpart this week, at a time when other U.S. industries face a tighter regulatory environment for business dealings in China under new national security legislation. Almost half of U.S. deals to license drugs from overseas in 2025 were with Chinese companies, and China signed licensing deals worth a total $110B in the first half of 2026.

Goldman Sachs has identified Chinese healthcare stocks as a key post-AI growth opportunity, with pharmaceutical names accounting for one-third of the 12 companies that made its final screen. In a Sept. 7 report, the firm's portfolio strategy research team said nearly half of MSCI China index constituents beat estimates in the second quarter, led by IT and healthcare, and that Chinese stocks' earnings tracked by Goldman Sachs grew at their highest quarterly pace in five years at 24% in the second quarter from a year ago, accelerating from just 6% in the first quarter. The analysts screened their buy-rated coverage for Chinese companies with expected earnings growth of more than 15% annually through 2027 and an increase in earnings per share estimates by a median of 7% over the past month. The four healthcare names on the list are Suzhou-based Innovent Biologics, whose earnings are expected to more than double in the year ahead with Goldman's estimate 54 percentage points above consensus; Shanghai-listed BeOne Medicines, also expected to more than double; Hong Kong-listed CSPC, forecast to grow 26%; and Hong Kong-listed Hansoh Pharma, forecast to grow 15%. Goldman expects MSCI China earnings to grow by 8% this year, far more conservative than the consensus forecast for 17%.

Beijing Aosaikang Pharmaceutical Co., Ltd. disclosed its 2026 semi-annual report on the evening of August 27. During the reporting period, it achieved operating revenue of 871 million yuan, net profit attributable to shareholders of the listed company of 121 million yuan, and R&D investment of 293 million yuan, accounting for 33.68% of revenue. The company's core innovative drug, limertinib tablets, in a Phase III clinical study for first-line treatment of EGFR-sensitive mutation advanced non-small cell lung cancer, showed a median progression-free survival of 20.7 months, reducing the risk of disease progression or death by 56%. In patients with brain metastases, median progression-free survival was also 20.7 months, with a 72% risk reduction. Overall survival data were presented at the 2026 European Lung Cancer Congress, with median overall survival reaching 43.3 months. Since January 1, 2026, two indications of this drug have been covered under the national medical insurance reimbursement standards, and the company has entered into a commercialization partnership with Innovent Biologics. In terms of the pipeline, the marketing application for ASKC109 has been accepted, the Phase III clinical trial of ASKC202 combination therapy is progressing, ASKC189 is undergoing Phase I studies simultaneously in China and the United States, and ASKB589 has completed patient enrollment. The company has seven active pharmaceutical ingredient production lines and thirteen formulation production lines, and has passed GMP certification more than sixty times.

In early trading on August 20, innovative drug stocks surged at the open. Sanyuan Gene, Jiankai Technology, Walvax Biotechnology, Laimei Pharmaceutical, CanSino Biologics, Youcare Pharmaceutical, Shuanglu Pharmaceutical, and Baike Bio hit their daily limit up at the open, while Zhifei Biological, CSPC Innovation, and Kangtai Biological rose more than 10%. On the news front, Merck and Moderna announced on Wednesday that the first Phase III clinical trial of their jointly developed mRNA personalized cancer vaccine, intismeran autogene, produced preliminary positive results. Moderna's stock price soared nearly 180% in overnight U.S. trading. Among exchange-traded funds, the GF Hong Kong Innovative Drug ETF rose as much as 7%, the GF Hang Seng Biotech ETF and GF Medical ETF rose as much as 6%, and the GF Innovative Drug ETF and GF Pharmaceutical ETF followed higher. On the industry side, innovative drug listed companies have been releasing their 2026 interim reports and earnings forecasts in a concentrated manner. The industry is officially welcoming a triple earnings inflection point: commercialization of blockbuster single products, realization of overseas business development deals, and high prosperity across the entire upstream CXO chain. Blockbuster products such as zanubrutinib and mazdutide have achieved scaled profitability, while CSPC Pharmaceutical Group, Hengrui Pharmaceuticals, and Innovent Biologics have successively landed overseas business development deals worth billions of dollars. CXO leaders have seen profits and orders simultaneously hit record highs.

OPKO Health expanded its strategic financing relationship with HealthCare Royalty by issuing $125 million of senior secured notes backed by its royalty interests from the mazdutide license agreement with Eli Lilly. The notes are secured by OPKO's royalty interests arising from its mazdutide licensing agreement with Eli Lilly and are scheduled to mature in 2044, in line with the maturity of OPKO's existing HealthCare Royalty notes issued under the original financing arrangement. Total payments under the expanded financing structure are capped at 1.5 times the amount funded, after which OPKO will retain the future royalty economics associated with the financed stream. Mazdutide is being commercialized in China by Innovent Biologics under OPKO's licensing arrangement with Eli Lilly, with OPKO entitled to royalties on commercial sales, and the company recorded its initial mazdutide royalty revenues in 2025 following the product's commercial launch activities in China. HealthCare Royalty, which is majority owned by KKR and has committed more than $7 billion across more than 110 biopharmaceutical products since its founding in 2006, views mazdutide as an attractive opportunity given its exposure to the high-growth Chinese market.

Spero Therapeutics announced it has extended its cash runway into the second half of 2029 following the closing of a $105 million nondilutive, nonrecourse royalty financing with Healthcare Royalty. The notes carry a 10% annual interest rate and a 9-year maturity, and after repayment Spero retains 35% of additional GSK milestone and royalty proceeds. The company also highlighted the FDA approval of Utebzi, the first and only oral carbapenem antibiotic approved in the United States, with GSK expecting U.S. availability in the second half of this year. Additionally, Spero in-licensed SP001 from Innovent Biologics for an estimated $1.1 billion in total contingent deal value, gaining exclusive worldwide rights excluding Greater China, and plans to advance SP001 in IgG4-related disease with a Phase II trial expected to begin in the second quarter of 2027. For the second quarter of 2026, Spero reported no revenue compared with $14.2 million a year earlier, research and development expenses of $3.4 million versus $10.7 million, and a net loss of $9.6 million, or $0.16 per share.

On August 13, China's A-share pharmaceutical sector strengthened, with Boji Medical and Longshen Rongfa up by the 20 percent daily limit, Fangsheng Pharmaceutical and Jiuzhou Pharmaceutical up by the 10 percent daily limit, and innovative drug companies such as Yahong Meditech, Junshi Biosciences, Dizal Pharmaceutical, and Zhongsheng Pharmaceutical rising more than 3 percent. Since WuXi AppTec released its better-than-expected 2026 interim report on August 3, the pharmaceutical sector has kept climbing, with Wanbang Pharmaceutical posting three boards in two days, Yatai Group three consecutive daily limits, and Yuyuan Pharmaceutical four boards in five days. Southwest Securities research argues that WuXi AppTec's interim net profit attributable to the parent exceeded 10 billion yuan for the first time and raised its guidance, while BeiGene, RemeGen, and Innovent Biologics released positive results at the same time, creating a sector-wide resonance effect. WuXi AppTec's first-half revenue was 28.9 billion yuan, up 38.93 percent year on year, with net profit attributable to the parent of 11.08 billion yuan, up 29.43 percent. BeiGene's first-half total revenue was 22.22 billion yuan, up 26.8 percent year on year, with net profit attributable to the parent of 3.271 billion yuan, up 627.1 percent, and it raised its full-year revenue guidance to between 44.9 billion and 46.2 billion yuan. Innovent Biologics' first-half product revenue exceeded 8.2 billion yuan, up more than 55 percent year on year. In addition, Akeso's ivonescimab injection combined with chemotherapy was approved for first-line treatment of advanced squamous non-small cell lung cancer, marking the drug's third indication in lung cancer. On August 10, China's pharmaceutical industry announced three deals, including a collaboration between BeiGene and Revolution Medicines, a partnership between Innovent Biologics and Daiichi Sankyo, and a collaboration between Gan & Lee Pharmaceuticals and Menarini, with a potential total transaction value of 726 million euros. On August 12, CSPC Pharmaceutical Group received a 30 million US dollar upfront payment from AstraZeneca. Xiangcai Securities research argues that this round of the pharmaceutical sector's rally will be significantly more durable than previous ones, based on three judgments: the pharmaceutical sector absorbing capital outflows from the technology sector, improving interim results from CXO companies, and the initial emergence of Chinese pharmaceutical companies' global expansion.

Pfizer stock has risen 6.9% since it reported second-quarter 2026 results on August 4, beating earnings and revenue estimates. The company raised the lower end of its 2026 revenue guidance to a range of $60.5 billion to $62.5 billion, up from $59.5 billion to $62.5 billion, while reaffirming adjusted earnings guidance of $2.80 to $3.00 per share, which now includes a 10-cent charge from a licensing deal with Innovent Biologics. Non-COVID product revenues grew 5% operationally excluding Comirnaty and Paxlovid, offsetting declining COVID product sales, which are now expected to total approximately $4 billion in 2026, down from a prior forecast of $5 billion. The company faces a loss of exclusivity cliff expected to reduce revenues by about $1.1 billion in 2026, but is advancing a pipeline in oncology and obesity, including the GLP-1 candidate berobenatide with potential approvals starting in 2028. Pfizer shares trade at a forward price-to-earnings ratio of 9.08, below the industry average of 18.53 and its five-year mean of 9.28, and offer a dividend yield of around 6.4%.

Innovent Biologics has entered into an exclusive agreement with Daiichi Sankyo to commercialize the FLT3 inhibitor VANFLYTA in China. Under the deal, Innovent gains marketing and distribution rights while Daiichi Sankyo retains manufacturing and supply responsibilities. VANFLYTA is approved in Japan, the U.S., and Europe for relapsed or refractory FLT3-ITD positive acute myeloid leukemia, an aggressive blood cancer with poor prognosis. Innovent will leverage its Chinese commercial infrastructure to expand access, and Daiichi Sankyo will receive upfront and milestone payments plus royalties on net sales.

China's A-share market opened higher across the three major indices, with Baihua Pharmaceutical locking in its fifth consecutive daily limit-up. The Shanghai Composite Index opened 0.10% higher, the Shenzhen Component Index rose 0.27%, and the ChiNext Index edged up 0.11%, as over 2,700 stocks advanced. Baihua Pharmaceutical had previously announced that its stock price deviation over three consecutive trading days from August 3 to August 5 exceeded 20%, triggering abnormal trading volatility, but a self-inspection revealed no undisclosed material information and normal operations. On the news front, total out-licensing deal value for Chinese innovative drugs in the first half of 2026 reached approximately 99.7 billion US dollars, roughly double the full-year figure for 2024. BeiGene raised its full-year performance forecast, while RemeGen and Innovent Biologics reported significantly improved results. A research note from Sinolink Securities pointed out that as of July 10, 2026, external capital expenditure by the top 15 global pharmaceutical companies this year had reached 200.3 billion US dollars, approaching 73.5% of the full-year total for 2025, largely confirming a high-activity M&A cycle in the global pharmaceutical industry.

Penghua STAR 100 ETF surged over 2% in morning trading, with semiconductor and pharmaceutical sectors rallying strongly. On the news front, DeepSeek plans to raise API service pricing soon, with a significant increase expected. Goldman Sachs noted that demand for Chinese AI models is robust and computing power is tightening, with industry competition shifting from price wars back to rational pricing. In pharmaceuticals, the total out-licensing deal value for Chinese innovative drugs in the first half of 2026 reached approximately 99.7 billion US dollars, roughly double the full-year figure for 2024. BeiGene raised its full-year operating performance forecast, while RemeGen and Innovent Biologics reported substantially improved results. BOC International analysis indicates that since 2026, global semiconductor materials have seen a wave of price hikes, covering core categories such as silicon wafers, electronic specialty gases, and sputtering targets. This is driven by a combination of surging AI computing demand, rising costs from Middle East geopolitical conflicts, and supply constraints on certain metal raw materials, opening an accelerated substitution window for domestic material companies. As of 10:13 AM on August 7, 2026, the SSE STAR 100 Index rose strongly by 2.23%, with constituent ChipMOS Technologies up 12.22%, InventisBio up 8.15%, and Fortrend Precision up 6.87%. Penghua STAR 100 ETF closely tracks this index, with the latest price at 1.75 yuan, aiming for a fourth consecutive gain.

The clinical trial applications for two oral weekly GLP-1 drugs, Innovent Biologics' IBI3042 and Gan & Lee Pharmaceuticals' GZC8072 tablets, have been accepted by the National Medical Products Administration. IBI3042 is the world's first small-molecule weekly GLP-1 drug to enter the clinical stage. Recently, Hengrui Medicine achieved three key milestones, including the approval of famitinib combined with camrelizumab for first-line treatment of PD-L1 positive cervical cancer. The number of oral presentations by Chinese innovative drugs at the ESMO Congress hit a new high, which Soochow Securities believes signals China's growing influence in research and development. In the first half of this year, 38 innovative drugs were approved for marketing, of which 31 were domestically developed, accounting for over 80 percent. The total value of out-licensing deals for innovative drugs exceeded 100 billion dollars.

On the morning of July 15, the three major A-share indexes gave up early gains. By the midday break, the Shanghai Composite Index was down 0.08%, the Shenzhen Component Index down 0.38%, the ChiNext Index down 0.36%, and the STAR Composite Index down 2.72%. The pharmaceutical sector saw a broad rally, with GemPharmatech, ChemPartner, BrightGene Bio-Medical Technology, and Dizal Pharmaceutical all surging by the 20% daily limit. Over ten other stocks, including Joinn Laboratories, Haisco Pharmaceutical, and Baihua Pharmaceutical, also hit their daily limit. Harbin Pharmaceutical Group locked in its fourth consecutive daily limit. Baijiu stocks were all in positive territory, with Golden Seed Winery hitting the daily limit. Kweichow Moutai rose over 2%, Wuliangye Yibin over 3%, Shanxi Xinghuacun Fen Wine Factory over 6%, and Luzhou Laojiao nearly 6%. The semiconductor sector fell sharply, with Demingli hitting the daily limit down. Precious metals and communication equipment sectors were among the biggest decliners. In news, the National Healthcare Security Administration released the list of drugs that passed the formal review for the 2026 drug catalog adjustment. Meanwhile, the internationalization of Chinese innovative drugs is accelerating. Three outbound licensing deals by Dizal Pharmaceutical, Hansoh Pharmaceutical, and Innovent Biologics each reached several billion US dollars in total value. In the first half of 2026, the total value of Chinese pharmaceutical outbound deals reached 99.7 billion US dollars, already exceeding the full-year figure for 2024.

The Hang Seng Index climbed 340.37 points, or 1.4%, to 24,681.10 on the Hong Kong market on the 15th, marking a fourth consecutive advance. Easing expectations for US rate hikes provided support, as the probability of a rate increase at this month's FOMC meeting plunged to around 10% following slower growth in the June US consumer price index, also alleviating concerns over rising domestic interest rates in Hong Kong. However, gains were capped after China's April-to-June GDP growth came in at 4.3% during trading hours, missing the forecast of 4.5% and decelerating from 5.0% in the previous quarter. Among Hang Seng Index constituents, pharmaceutical stocks rose, with Innovent Biologics up 7.8% and WuXi AppTec up 4.4%, while Hong Kong property and AI-related shares also attracted buying. On the other hand, resource stocks fell, with Lingbao Gold Group down 5.5% and Chifeng Jilong Gold Mining down 5.1%.

Innovent Biologics has entered an exclusive licensing agreement with Spero Therapeutics for IBI355, a third-generation Fc-silent anti-CD40L antibody for autoimmune diseases, in a deal worth up to about $1.1 billion. Innovent will receive an upfront payment and is eligible for development, regulatory and commercial milestone payments, plus tiered royalties on net sales in Spero's licensed territories. Spero gains exclusive worldwide rights to develop, manufacture and commercialize IBI355 outside Greater China, while Innovent retains rights in Greater China. IBI355 has been evaluated in two Phase 1 studies in healthy volunteers and a Phase 1b study in patients with Sjögren's disease. Spero expects to start a Phase 2 trial in IgG4-related disease in the second quarter of 2027, and Innovent plans to begin a Phase 2 study in China for Sjögren's disease by early 2027.

The Sci-Tech Innovation Medical ETF Huaxia has reached a latest size of 249 million yuan, a nearly one-year high. The ETF has seen net inflows for 11 consecutive days, attracting a total of 139 million yuan, with an average daily net inflow of 12.6 million yuan. Huayuan Securities believes that after a decade of innovation and transformation, innovative drugs have significantly opened a new growth curve for Chinese pharmaceutical companies. The industry has reached a considerable scale, the trend of going overseas continues, while domestic aging demand and the improvement of the medical insurance payment system continue to drive incremental growth. The Hang Seng Medical ETF Huaxia closely tracks the Hang Seng Biotechnology Index, with the top ten holdings including Innovent Biologics, BeiGene, WuXi Biologics, and others, accounting for a combined 71.34%.

In the first half of 2026, the A-share Shenwan pharmaceutical and biotech sector remained sluggish, with the index falling 14.11% year-to-date, but the innovative drug supply chain bucked the trend. Traditional pharma companies faced operational pressure: Pian Zai Huang reported its first-ever decline in both revenue and net profit since listing, while Tong Ren Tang saw its revenue drop for the first time in five years. In contrast, BeiGene achieved its first full-year profit, and Hengrui Medicine's innovative drug sales exceeded 60% of total revenue for the first time. In the first half, total out-licensing deal value for domestic innovative drugs reached 99.7 billion dollars, roughly double the full-year total for 2024. This included an 18.5 billion dollar deal between AstraZeneca and CSPC Pharmaceutical Group, and an 8.5 billion dollar deal between Eli Lilly and Innovent Biologics. On the industrial capital front, 145 A-share pharma and biotech companies implemented share buybacks in the first half, totaling over 13.3 billion yuan, with innovative drug and CXO firms leading the charge. The secondary market's valuation logic is shifting from pipeline expectations to commercialization and overseas delivery. In the last week of June, the Shenwan pharmaceutical and biotech index rebounded 10.53% in a single week, while the innovative drug segment surged 17.06%.

Innovent Biologics has secured sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China under a new distribution and promotion agreement, while Lilly retains manufacturing, supply, and development responsibilities. Separately, Eli Lilly received a positive regulatory opinion in Europe for expanding the use of its cancer drug Jaypirca in chronic lymphocytic leukemia. These developments highlight how partnerships and oncology approvals are broadening Lilly’s reach beyond its dominant obesity and diabetes franchise, though they do not materially shift the near-term investment focus on GLP-1 access, pricing pressure, and concentrated product risk.

Eli Lilly has entered a new research collaboration with Abbisko Cayman Limited and transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics. The Abbisko partnership aims to expand Lilly's pipeline through external R&D, while the Verzenios agreement adjusts its commercial approach in the Chinese market. These moves highlight Lilly's strategy of using alliances to access additional science and respond to local conditions, beyond its core obesity and diabetes treatments. The outcomes will depend on research progress, regulatory decisions, and partner execution.

Eli Lilly is handing over the commercialization rights for its breast cancer drug Verzenio in mainland China to Innovent Biologics. Innovent will now have the sole right to commercialize the drug in mainland China, while Lilly will continue to manufacture, supply, and develop Verzenio. The drug has been available in China since 2021 and generated about 1.5 billion yuan, or $221 million, in sales last year, according to Jefferies data cited by Reuters. The move comes as Lilly anticipates increased competition, with Chinese regulators having approved a generic version from a Qingfeng Pharmaceutical unit, though analysts expect it may not reach the market until Lilly's patent expires in late 2029.

Ollin Biosciences has completed an oversubscribed $330 million Series B financing co-led by TCGX and ARCH Venture Partners. The funds will support global Phase 3 trials of OLN324, a next-generation VEGF/Ang2 bispecific antibody, in diabetic macular edema and wet age-related macular degeneration, with studies expected to begin in the second half of 2026. In a head-to-head proof-of-concept study, OLN324 demonstrated faster and greater retinal drying and numerically greater vision gains compared to Vabysmo. Ollin has completed an End-of-Phase 2 meeting with the FDA and received scientific advice from the EMA on the Phase 3 program. Innovent Biologics, which discovered the molecule and is Ollin's partner, will include China and South Korea in the global trials.

Innovent Biologics has dosed the first patient in the Chinese pivotal Phase 3 clinical trial of its self-developed tri-specific antibody IBI3003 for relapsed or refractory multiple myeloma. The trial, called TriadicMM-1, is a multicenter, randomized, controlled, open-label study evaluating IBI3003 against investigator's choice of either PVd or DPd, with progression-free survival as the primary endpoint. IBI3003 targets GPRC5D, BCMA, and CD3, and is China's first self-developed tri-specific antibody to enter a pivotal registrational Phase 3 trial. Earlier Phase 1/2 data presented at the 2025 ASH meeting showed an 83.3% overall response rate among patients treated at doses of at least 120 μg/kg, with all cytokine release syndrome cases being Grade 1-2. The therapy has also received Fast Track Designation from the U.S. FDA for patients who have received four or more prior lines of therapy.